

## **CURRENT REPORT 26/2020**

### **July 30, 2020**

## **Introduction of the Rights to Series I Shares to trading on the main market operated by the WSE**

With reference to the current report no. 22/2020 (dated July 13, 2020), no. 23/2020 (dated July 15, 2020), no. 24/2020 (dated July 22, 2020) and no. 25/2020 (dated July, 27 2020) the Management Board of Ryvu Therapeutics SA with its registered office in Kraków ("Company") hereby announces that the Warsaw Stock Exchange ("WSE") by virtue of the Resolution no. 553/2020, decided to introduce 2,384,245 Rights to Series I Shares ("Rights to Shares") marked by the National Depository of Securities with the code "PLSELVT00054" to trading on the main market as of July 31, 2020.

Rights to Shares will be listed in the continuous quotation system under the abbreviated business name "RYVU-PDA" and designation "RVUA".

**Legal basis:** Article 56.1.2 of the Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organised Trading and Public Companies, dated 29 July 2005

#### **Representatives of the Company:**

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board